The safety and efficacy of Herceptin in women receiving adjuvant chemotherapy for HER2 overexpressing breast cancer, were eva luated in an integrated analysis of two randomized, open‑label, clinical trials (Studies1 and 2) with a total of 3752women, a third randomized, open‑label, clinical trial (Study3) with a total of 3386women, and a fourth randomized, open‑label clinical trial with a total of 3222patients (Study4).

Studies 1 and 2

In Studies1 and 2, breast tumor specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH). HER2 testing was verified by a central laboratory prior to randomization (Study 2) or was required to be performed at a reference laboratory (Study 1). Patients with a history of active cardiac disease based on symptoms, abnormal electrocardiographic, radiologic, or left ventricular ejection fraction findings or uncontrolled hypertension (diastolic > 100mmHg or systolic > 200mmHg) were not eligible.

Patients were randomized (1:1) to receive doxorubicin and cyclophosphamide followed by paclitaxel (AC→paclitaxel) alone or paclitaxel plus Herceptin (AC→paclitaxel + Herceptin). In both trials, patients received four 21‑day cycles of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2. Paclitaxel was administered either weekly (80mg/m2) or every 3 weeks (175 mg/m2) for a total of 12weeks in Study 1; paclitaxel was administered only by the weekly schedule in Study 2. Herceptin was administered at 4mg/kg on the day of initiation of paclitaxel and then at a dose of 2mg/kg weekly for a total of 52weeks. Herceptin treatment was permanently discontinued in patients who developed congestive heart failure, or persistent/recurrent LVEF decline [see Dosage and Administration (2.2)]. Radiation therapy, if administered, was initiated after the completion of chemotherapy. Patients with ER+ and/or PR+ tumors received hormonal therapy. Disease‑free survival (DFS), defined as the time from randomization to recurrence, occurrence of contralateral breast cancer, other second primary cancer, or death, was the main outcome measure of the combined efficacy analysis.

A total of 3752patients were included in the efficacy analyses. The data from both arms in Study 1 and two of the three study arms in Study 2 were pooled for efficacy analyses. Of these patients, the median age was 49years (range, 22–80 years; 6% > 65 years), 84% were white, 7% black, 4% Hispanic, and 4% Asian/Pacific Islander. Disease characteristics included 90% infiltrating ductal histology, 38% T1, 91% nodal involvement, 27% intermediate and 66% high grade pathology, and 53% ER+ and/or PR+ tumors. At the time of randomization 53% of the population were to receive paclitaxel on a weekly regimen, and the remainder were to receive a q3week schedule of paclitaxel.

Study3

In Study 3, breast tumor specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH) as determined at a central laboratory. Patients with node‑negative disease were required to have ≥ T1c primary tumor. Patients with a history of congestive heart failure or LVEF <55%, un